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Plasma cholesterol esters are formed within the circulation bylecithin-cholesterol acyltransferase(LCAT),
an enzyme produced by the liver. Patients with hepatocellular disease have low plasma LCAT activity. This
largely accounts for the decreased levels of cholesterol esters observed in such patients and appears due to
impaired hepatic production of the enzyme. In contrast, activity of the LCAT reaction in patients with
cholestasis seems variable and is the subject of controversy, largely because the influence of abnormal
cholestatic lipoproteins on the reaction requires further clarification.
Human liver contains a lysosomal cholesterol ester hydrolase (CEH) which may play an important role in
hepatic cholesterol homeostasis. In patients with liver damage there is no concrete evidence of circulating
CEH activity, but recent studies show elevated activity of hydrolase within the liver itself in acute hepatitis.
Hepatic activity of another lysosomal enzyme, acid phosphatase, is not increased, suggesting that high CEH
in hepatitic liver does not simply reflect a general increase in lysosomal enzymes. The pathogenesis and
significance of altered CEH activity in liver disease require further study.
It is a particular pleasure for me to participate in this Festschrift honoring
Professor Gerald Klatskin, as he has had a major influence on my life. Among other
things, Dr. Klatskin stimulated my interest in lipid metabolism when I was a Fellow
in his Liver Study Unit at Yale a decade ago. Because ofthis, I have chosen to discuss
selected aspects of cholesterol ester metabolism in human liver disease. Emphasis will
be on contributions in which I have been personally involved.
THE LCAT REACTION AND LIVER DISEASE
In healthy individuals about two-thirds of the serum cholesterol exists in esterified
form. It was long assumed that these cholesterol esters were formed directly by the
liver, but in a series of brilliant experiments in the 1960s Glomset showed that they
were in fact formed primarily in the circulation [1]. The basis for this concept dates
back to 1935, when Sperry noted that plasma or serum standing at 37°C develops a
progressive increase in cholesterol ester concentration with no change in total
cholesterol [2]. Glomset's work 30 years later showed that this plasma esterification
reaction is due to a circulating enzyme, lecithin-cholesterol acyltransferase (LCAT)
[1,3,4]:
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Lecithin + Free Cholesterol Cholesterol Ester + Lysolecithin
During the past decade the biochemistry of this reaction has been studied in great
detail. Study of the reaction was stimulated by the 1967 discovery by Norum and
Gjone of a few patients in Scandinavia with familial LCAT deficiency [5]. Subse-
quent thorough investigation ofthis rare disorder has greatly advanced knowledge of
normal lipoprotein metabolism [4,6,7]. The LCAT reaction is extraordinarily
complex and has already been the subject of two international symposia, the first in
Oslo in 1973 and the second just recently in London in May 1978. Reviews of the
subject have been provided by Glomset [3,4] and by the proceedings of the two
symposia [6,8].
LCAT is present in the infranatant fraction of serum subjected to ultracentrifu-
gation at density 1.21 [9]. Early investigations suggested that the enzyme reacts with
both "nascent" high density lipoproteins (HDL) and low density lipoproteins (LDL)
as substrate, primarily the former [1,3]. A HDL protein, later identified as apo-AI,
was shown to act as co-factorfor the reaction by Fielding et al. in 1972[10]. Lipids in
very low density lipoproteins (VLDL) were thought to be only indirectly influenced
by LCAT via non-enzymatic lipid exchange among lipoprotein fractions [3]. These
views may need to be modified, in view of evidence presented at the recent London
symposium. Studies with partially purified enzyme and various lipoproteinfractions,
with serum from patients with Tangier disease (who lack HDL), and with apopro-
teins such as apo-AI and apo-C, have yielded complex and conflicting data on the
biochemistry of the LCAT reaction, particularly the preferred substrate and the role
of apoprotein co-factors [8]. Moreover, the physiological role of the reaction is not
certain [8], although present evidence suggests that it plays an important part in
triglyceride turnover and in prevention of plasma accumulation of "excess" free
cholesterol derived from the surface of chylomicrons and VLDL [4,7].
LCAT in Parenchymal Liver Disease
My own interest in LCAT is clinical and centers around its activity in patients with
liver disease. It has long been known that the ratio of esterified to free serum
cholesterol is decreased in hepatobiliary disorders. In parenchymal liver disease this
abnormality was traditionally ascribed to decreased ester synthesis by the damaged
liver. With clarification of the LCAT reaction in the late 1960s. however, it became
appropriate to examine whether low ester levels in liver disease could in fact be due
to impaired formation within the circulation. Indeed, this possibility had actually
been hinted at in the older literature [1 1,12], longbefore the nature ofthe cholesterol
esterification reaction was understood.
Dr. Bob Scheig and I decided to examine this question. We first modified available
techniques to develop a clinical LCAT assay based on the ability of test serum to
esterify '4C-cholesterol-labeled substrate, then applied the assay to healthy subjects
and patients with a variety of hepatic disorders [13]. Results showed that serum
LCAT activity was indeed diminished in most patients with hepatocellular disease.
Moreover, the degree of LCAT impairment generally paralleled the severity of
hepatic dysfunction, and the percent cholesterol esters in the serum correlated with
the patient's LCAT status [13]. Similar observations were made independently by
Gjone and Norum in Norway [14], and other authors have subsequently confirmed
these findings [15-17]. There is now general agreement that impaired LCAT activity
is an important factor in the pathogenesis of serum lipid derangements in patients
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with hepatocellular disease, although the complex lipoprotein disturbances in these
patients cannot be entirely explained by this abnormality [18,19].
Attention was next directed to the pathogenesis of the low LCAT activity.
Although deficient production of LCAT by damaged liver seems the most likely
cause, several other explanations are theoretically possible. First, circulating LCAT
inhibitors, for example bile salts [1], could be present in these patients' sera. We
studied this possibility in a series of cross-incubation experiments, but found that
serum from patients with liver disease did not inhibit the LCAT activity of normal
serum [13]. Other authors have carried out similar studies and also have found that
circulating LCAT inhibitors are not the cause of the low cholesterol esterification in
liver disease [15]. Second, there could be a deficiency of LCAT activators in hepatic
dysfunction. This possibility, however, has also been excluded by cross-incubation
studies with normal serum [15].
A third possibility is the presence of abnormal substrate lipoproteins in the
patients' sera, rather than a deficiency of LCAT itself. This explanation is not so
readily excluded, because autologous lipoproteins are present in any patient's serum
being assayed. This technical difficulty can be partly circumvented, however, by
incubating relatively small amounts of test serum with relatively large amounts of
substrate serum. We did this in a group of patients with hepatocellular disease, in
each case assaying the patient's serum simultaneously with both autologous substrate
and normal substrate [20]. The source of substrate had little influence on the assay,
indicating that decreased cholesterol esterification was in fact not due primarily to
abnormal substrate lipoproteins [20]. Blomhoff et al. reached the same conclusion
when they also considered this question [17].
Fourth, cholesterol ester hydrolase could be present in the circulation. Human
serum does not normally possess hydrolytic activity, but Stokke[21,22] has described
a lysosomal cholesterol ester hydrolase (CEH) in human liver, discussed in more
detail below. This enzyme could theoretically be released into the circulation by
damaged liver cells, a possibility raised by Jones et al. [23]. Ifso, the"net cholesterol
esterifying activity" of serum [23] would reflect an interaction between LCAT and
CEH rather than LCAT alone; CEH would oppose the action of LCAT and thereby
contribute to the observed decrease in serum cholesterol esterification. A few years
ago we investigated this possibility by simultaneously assaying both LCAT and net
esterifying activity, and also by searching directly for circulating hydrolase with a
specifically developed radioassay [24]. Results yielded no evidence of circulating
CEH activity, even in patients with profound hepatocellular dysfunction, and
therefore provided strong evidence against Jones' hypothesis [24].
From these and other results it appears most likely that diminished esterifying
activity in liver disease is duedirectly toimpaired synthesis or release ofLCAT bythe
damaged liver [19,20]. Experiments with the isolated perfused rat liver support this
explanation. Both I and Boyer [25] and Osuga and Portman [26] showed that the
isolated liver released LCAT into the perfusate progressively. This proved that the
enzyme is produced by the liver, and thereby provided a logical basis for the
diminished LCAT activity in hepatocellular disease.
LCATin Cholestatic Liver Disease
The situation in cholestatic (obstructive) disorders appears more complex and
remains controversial. Like parenchymal liver disease, biliary obstruction is also
associated with a low ratio of esterified to free serum cholesterol, but this is usually
due primarily to an increase in free cholesterol rather than a decrease in cholesterol
119esters. The pathogenesis of the hypercholesterolemia is complex and has been
reviewed by McIntyre et al. [27]. Pioneer studies by Seidel and his associates [28,29]
established that serum from patients with cholestasis contains an abnormal lipopro-
tein, known as lipoprotein-X (LP-X), which can largely account for the in vivo lipid
characteristics both morphologically and chemically. Under the electron microscope
it appears as disc-shaped vesicles 300-700 angstroms in diameter which tend to
aggregate [30,31]. Compared to normal LDL, LP-X contains much higher amounts
of phospholipid and free cholesterol, smaller amounts of esterified cholesterol and
triglyceride, and less protein [28,30].
The status of the LCAT reaction in cholestasis is controversial. Initial reports
noted variable esterification of serum cholesterol in biliary obstruction [11,12,15].
These studies were based on long in vitro incubations, however, which reflect the
extent rather than the rate of esterification (substrate is rate-limiting to the LCAT
reaction after a relatively short incubation time). Experiments involving briefer
incubations with sensitive methods for measuring the small amount of cholesterol
esterified, such as gas-liquid chromatography or use oftrace amounts of radiolabeled
cholesterol incorporated into substrate serum lipoproteins, are therefore preferable.
Using the latter technique, I and Scheig initially found normal or high LCAT activity
in a few patients with cholestasis who were part of our larger group of patients with
liver disease [13]. In contrast, Gjone in Norway reported low LCAT activity in
patients with obstructive jaundice [14,32]; he also used a radioassay but with some
technical differences from our own. Subsequent studies by other authors also yielded
variable and conflicting results (summarized in [20]).
To study further these discrepancies I simultaneously assayed LCAT activity by
both our own method and the technique used by Gjone [20]. Results showed
excellent correlation between the two methods, indicating that technical factors were
not solely responsible for the disparate results. Instead, differences in the severity and
duration of cholestasis, and thus of secondary hepatocellular damage, appeared to be
the likely explanation [20]. In separate experiments, we carried out further studies in
patients with cholestasis, using both an isotopic and a colorimetric LCAT assay
[33]. Results confirmed our initial findings of normal or increased activity in
autologous patient serum. However, by cross-incubating normal and patient sera we
found that cholestatic serum regularly stimulated the LCAT reaction of normal
serum. Thus substrate lipoproteins in cholestasis (perhaps LP-X) appear to have a
major influence on the LCAT assay, unlike the usual situation in primary hepatocel-
lular dysfunction [33].
These and other results suggest that the overall LCAT reaction in obstructive
jaundice reflects a complex interaction among cholestatic lipoproteins, LCAT
deficiency due to concomitant hepatocellular damage, and possibly other unknown
factors [20,33,34]. Because of these variables, particularly the influence ofcholestatic
lipoproteins, LCAT activity per se in patients with cholestasis remains controversial.
A closely related and similarly controversial issue is whether LP-X itselfserves as a
substrate for the LCAT reaction. We were the first to suggest this possibility, in 1970
[13] and again in 1973 [33], based on our experimental findings plus speculation that
the high content of free cholesterol and lecithin in LP-X should theoretically provide
a particularly good substrate for LCAT. Wengeler and Seidel, however, concluded
that LP-X is not in fact a LCAT substrate [35]. In contrast, Ritland and Gjone, using
different experimental methods, reached the opposite conclusion [36]. Most recently,
Patsch et al. reported that LP-X is indeed a substrate for purified LCAT [37]. It is
apparent, however, that the issue is far from being settled.
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The most important factor making uncertain the activity of LCAT in obstructive
jaundice is the presence of cholestatic lipoproteins in the plasma or serum being
tested. All clinically applicable LCAT assays to date, whether based on changes in
cholesterol concentration in autologous plasma or on use of a standard non-
autologous substrate, have been subject to this difficulty. However, a new LCAT
assay devised within the past year by Alcindor and his colleagues in Paris may
obviate this hitherto unavoidable problem. Their assay has been partly published in
French [38] and was presented at the May 1978 LCAT symposium in London [39].
Through subsequent personal correspondence, Alcindor has kindly sent me details of
the method (personal communication, June 1978).
The crux of Alcindor's technique is complete delipoproteinization of the test
plasma in which LCAT is to be assayed. This is achieved by dextran sulphate-CaCl2
precipitation in the presence of a stabilized emulsion oftriglyceride and phospholipid
[38,39]. Valid clinical application of this new assay, however, will require proof that
the delipidation step does not concomitantly affect LCAT in the test plasma, and also
that it efficiently removes LP-X and other abnormal lipoproteins equally as well as
normal lipoproteins. We are planning experiments to assess these points. If success-
ful, use of Alcindor's assay may settle some ofthe uncertainties about LCAT activity
in patients with cholestasis.
CHOLESTEROL ESTER HYDROLASE IN HUMAN LIVER
Hepatic cholesterol esterifying and cholesterol ester hydrolysing enzymes were
characterized long ago in the rat [40]. Virtually nothing was known about these
enzyme systems in man, however, until the studies of Stokke a few years ago [21]. He
found that, in striking contrast to rat liver, human liver does not contain cholesterol
esterifying systems at a neutral pH even with the addition of various co-factors. A
reversible cholesterol esterase, however, is present at acid pH. This enzyme has
maximal hydrolysing activity at pH 4.5-5.0, with some tailing to neutral pH. The
hydrolase requires no co-factors, is stimulated by low concentrations of the surfac-
tant Triton X-100, and is inhibited by sulfhydryl-blocking agents [21]. Stokke
subsequently established that this acid cholesterol ester hydrolase (CEH) is of
lysosomal origin in the calf, and presumably also in man [22].
The physiological significance of this enzyme is as yet unknown, but theoretical
considerations favor an important role in lipoprotein cholesterol ester metabolism.
First, two rare diseases are known to be associated with deficient hepatic acid lipase
activity, Wolman's disease and cholesterol ester storage disease [41,42]; in both
conditions abnormal hepatic accumulation of cholesterol ester occurs. Second, in
order to maintain constant ester levels in the circulation, tissue uptake and hydrolysis
of plasma cholesterol esters must balance their formation. Since the liver is the major
site of lipoprotein clearance from blood [7], it should logically also be the site of
cholesterol ester hydrolysis. Third, cholesterol is excreted from the liver as lipopro-
tein free cholesterol, biliary excretion of free cholesterol, and conversion of free
cholesterol to bile acids. Thus circulating cholesterol esters entering the liver
presumably are hydrolysed to free cholesterol before further metabolism and turn-
over.
In addition to these theoretical points, recent experimental evidence suggests
involvement of CEH in hepatic lipoprotein catabolism. Cooper recently showed that
the perfused rat liver rapidly removes chylomicron remnants from the perfusate,
followed by hydrolysis of the cholesterol ester [43]. Similarly, using rat hepatocyte
monolayers, Floren and Nilsson observed an efficient degradation of cholesterol ester
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involvement [44]. In addition, Stein et al. recently studied the catabolism of VLDL
and LDL by rat liver, using chloroquine as an inhibitor of lysosomal enzymes, and
concluded that acid hydrolases participate in hepatic lipoprotein catabolism [45].
All of these recent results support the ideathat hepatic lysosomal hydrolases play a
major role in the physiologic degradation of plasma lipoproteins. To extend this
idea, the action of hepatic CEH on individual lipoprotein classes should be studied
in man, since results obtained using experimental animals may be subject to
complications arising from species differences in hepatic cholesterol esterifying
enzymes [21]. Such studies will require fresh human liver tissue as enzyme source,
with individual lipoprotein classes containing radiolabeled cholesterol ester as
substrate. Our current experiments with CEH activity in human liver needle biopsies
(see below) are well suited to this type of study, and we are planning studies to
examine directly the role of individual lipoprotein classes as substrate for hepatic
CEH in man.
CEH in Liver Disease
In theory, abnormal CEH activity in patients with primary hepatic disease might
affect the balance between cholesterol ester formation and breakdown, and thereby
contribute to lipid derangements. This could occur in at least two ways. First,
hydrolase could "leak" out of damaged hepatocytes and enter the circulation, where
it would oppose the esterifying action of LCAT [23]. As mentioned above, however,
we were unable to detect evidence of circulating CEH activity even in patients with
severe hepatic disease [24]. This does not entirely exclude the possibility that
circulating hydrolase is present in the occasional patient, but certainly CEH does not
usually contribute to the impaired serum cholesterol esterification observed in
hepatic disease.
Second, altered hydrolytic activity within the liver could affect homeostasis
between ester formation and hydrolysis. We have recently been studying this
possibility. We first had to develop a clinically useful CEH assay that could be
applied to portions of needle biopsy specimens. This was successfully accomplished
by working out a sensitive radioassay modified from Stokke's technique [21] and
validated in aseries ofpreliminary experiments on pH spectrum, kinetics, etc. Details
of this work havejust been published [46,47]. The assay enables CEH activity to be
determined in about 2 mg of liver homogenate, and is therefore suitable for clinical
studies on percutaneous needle biopsy specimens.
We then applied our CEH assay to a series of 69 patients undergoing diagnostic
liver biopsy for usual clinical indications [46]. In brief, we found that CEH activity
was more than threefold higher in liver homogenates from patients with acute
hepatitis than in histologically normal livers (p < 0.01). In contrast, hepatic CEH
activity was not significantly altered in alcoholic liver disease, obstructive jaundice,
or a group of miscellaneous liver disorders. Several pieces of evidence suggested that
the increased hydrolase activity in acute hepatitis was directly related to liver cell
necrosis. For example, CEH values correlated well with SGOT levels (r = 0.84) and
returned to normal as hepatitis resolved. However, we found no apparent relation-
ship to serum levels of either free or esterified cholesterol, nor to serum LCAT
activity determined concomitantly by radioassay [46].
Most recently we have turned our attention to the pathogenesis of the high CEH
activity in patients with hepatitis. The first question was whether the observed
abnormality reflected a nonspecific general increase in lysosomal activity; alterna-
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tively, CEH could be disproportionately elevated. The former possibility seems
reasonable, as viral hepatitis is associated with an increased size and number of
hepatocyte lysosomes [48]. To investigate this, in 41 patients we concomitantly
measured hepatic activity of CEH and of acid phosphatase, a standard lysosomal
marker enzyme [47]. Results showed that, unlike CEH, acid phosphatase activity is
not significantly increased in liver biopsy homogenates from patients with acute
hepatisis [47]. This disparity between the activity of the two lysosomal enzymes
suggests that high CEH activity is not simply a reflection of general enhanced
lysosomal activity.
One possible explanation for the discrepancy between CEH and acid phosphatase
activities is that the two enzymes have different solubilities. It is well established that
about 70 percent of total acid phosphatase activity is soluble when lysosomes are
disrupted [49] and that soluble lysosomal enzymes quickly disappear into the
circulation when released into the cytoplasm [50]. CEH might therefore be more
tightly bound to lysosomal membranes than acid phosphatase, or, if released, more
easily adsorbed by other subcellular fractions.
In recent months we have been directly comparing hepatic CEH activity with that
of other lysosomal enzymes of differing solubilities-specifically, P8-galactosidase,
known to be highly soluble [50,51], and N-acetyl-,P-glucosaminidase, which in
contrast is known to have a high affinity for subcellular fractions [51,52]. For further
comparison, acid esterase and cathepsin D, two other lysosomal enzymes, have also
been assayed. This was done by scaling down established methodologies with only
minor modifications, which has enabled us to use the small amounts of homogenate
we obtain from human percutaneous biopsy specimens. All assays are done after
alternately freezing and thawing the homogenates several times to ensure rupture of
lysosomes and hence measurement of total enzyme activity. Results to date have
revealed that CEH activity quiie closely parallels activity of each of the above
enzymes, with correlation coefficients of 0.77 to 0.90 (unpublished observations).
This argues against differences in solubility as an explanation for the high CEH
activity in hepatic liver.
An important, as yet untested possibility, is that the hydrolase is mainly derived
not from hepatocytes, but rather from Kupffer cell hyperplasia and/or mononuclear
cell infiltration (these two findings are important histologic features of acute
hepatitis). Although there are no direct data on this point, four recent pieces of
evidence in the literature make the postulate seem reasonable. First, CEH activity has
been detected in blood monocytes [53]. Second, Drevon et al. have shown that non-
parenchymal cells of rat liver (largely Kupffer cells) contain acid CEH activity
approximately equivalent to that of parenchymal cells [54]. Third, in a recent
preliminary communication Ganguly et al. have reported increased lysosomal
enzyme release in blood monocytes from patients with chronic liver disease, inflam-
matory bowel disease, and rheumatoid arthritis [55]. Finally, Van Berkel et al. have
very recently reported studies on the in vitro degradation of 12-labeled LDL and
HDL by liver homogenates, and found that a proportion ofthe rat's hepatic capacity
for lipoprotein degradation is localized in non-parenchymal cells [56]. These observa-
tions suggest a possible link between non-parenchymal cell function and our own
observations on increased hepatic CEH activity in human hepatitis.
CONCLUDING COMMENTS
Cholesterol ester formation and hydrolysis in liver disease is a complex subject,
and I have touched on only selected aspects in the above survey. Yet even within the
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narrow confines of my discussion it is apparent that much has yet to be learned. For
example, how many of the complex lipoprotein derangements associated with
hepatic disease can be ascribed to impaired LCAT activity? What is the clinical
importance of LCAT deficiency in parenchymal liver disease? How do cholestatic
lipoproteins influence the LCAT reaction, and does LP-X act as substratefor LCAT,
either directly or indirectly? Is LCAT activity per se low, normal, or high in
cholestasis? What is the role of hepatic lysosomal CEH in normal lipoprotein
catabolism? Are hepatocytes or non-parenchymal cells the primary source ofCEH in
man? Why is hepatic CEH activity increased in acute hepatitis, and what effect does
this have on cholesterol ester homeostasis?
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